| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 24.017 | 20.466 | 20.919 | 23.124 | 25.321 | 18.223 | 29.526 | 34.132 | 29.049 | 32.540 |
| Total Income - EUR | 24.038 | 21.063 | 20.933 | 23.124 | 25.321 | 18.223 | 29.526 | 35.404 | 29.810 | 35.382 |
| Total Expenses - EUR | 23.326 | 15.691 | 12.273 | 13.745 | 13.551 | 13.885 | 16.039 | 19.634 | 19.151 | 23.256 |
| Gross Profit/Loss - EUR | 712 | 5.372 | 8.660 | 9.379 | 11.771 | 4.338 | 13.487 | 15.770 | 10.658 | 12.126 |
| Net Profit/Loss - EUR | -9 | 5.004 | 8.450 | 9.148 | 11.517 | 4.170 | 13.221 | 15.435 | 10.375 | 11.144 |
| Employees | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Dr.vanghele Snc
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 578 | 20.837 | 19.707 | 18.581 | 17.473 | 18.017 | 16.712 | 22.617 | 20.829 | 19.002 |
| Current Assets | 1.321 | 6.289 | 9.348 | 18.732 | 30.674 | 33.987 | 47.088 | 44.353 | 53.580 | 61.525 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 250 | 0 |
| Receivables | 33 | 33 | 18 | 18 | 18 | 196 | 38 | 39 | 22 | 11 |
| Cash | 1.288 | 6.257 | 9.329 | 18.714 | 30.656 | 33.791 | 47.049 | 44.313 | 53.307 | 61.514 |
| Shareholders Funds | -7.521 | 18.631 | 26.766 | 35.423 | 46.254 | 49.547 | 56.894 | 66.300 | 72.572 | 79.403 |
| Social Capital | 129 | 128 | 126 | 124 | 121 | 119 | 116 | 117 | 116 | 116 |
| Debts | 9.350 | 8.495 | 2.288 | 1.890 | 1.893 | 2.457 | 6.906 | 670 | 1.836 | 1.124 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8623 - 8623" | |||||||||
| CAEN Financial Year |
8623
|
|||||||||
Comments - Dr.vanghele Snc